First therapy in sarcoidosis to reduce steroid burden while demonstrating improvements in key physiologic and quality of life measures. Global pivotal Phase 3 EFZO-FIT™ study currently enrolling. SAN DIEGO , Nov. 09, 2022 (GLOBE NEWSWIRE) -- aTyr Pharma, Inc.

Management to host conference call and webcast on November 10th at 5:00 pm EST / 2:00 pm PST SAN DIEGO , Nov. 03, 2022 (GLOBE NEWSWIRE) -- aTyr Pharma, Inc. (Nasdaq: LIFE), a biotherapeutics company engaged in the discovery and development of first-in-class medicines from its proprietary tRNA

SAN DIEGO , Oct. 25, 2022 (GLOBE NEWSWIRE) -- aTyr Pharma, Inc. (Nasdaq: LIFE), a biotherapeutics company engaged in the discovery and development of first-in-class medicines from its proprietary tRNA synthetase platform, today announced that Sanjay S.

Collaboration aims to accelerate drug discovery and advance company’s tRNA synthetase platform SAN DIEGO , Oct. 11, 2022 (GLOBE NEWSWIRE) -- aTyr Pharma, Inc. (Nasdaq: LIFE) (aTyr or “the Company”), a biotherapeutics company engaged in the discovery and development of first-in-class medicines from

SAN DIEGO , Oct. 04, 2022 (GLOBE NEWSWIRE) -- aTyr Pharma, Inc. (Nasdaq: LIFE), a biotherapeutics company engaged in the discovery and development of first-in-class medicines from its proprietary tRNA synthetase platform, today announced that Sanjay S.

Compositions and methods patent covers antibodies targeting NRP2 which may have therapeutic applications in the areas of cancer and inflammation SAN DIEGO , Sept. 29, 2022 (GLOBE NEWSWIRE) -- aTyr Pharma, Inc. (Nasdaq: LIFE), a biotherapeutics company engaged in the discovery and development of

Multiple centers in the U.S. are open for enrollment for double-blind, randomized, placebo-controlled study. Primary endpoint will evaluate steroid-sparing effect of efzofitimod compared to placebo. EFZO-FIT™ builds on positive results from Phase 1b/2a study which demonstrated dose dependent

Second Fast Track designation for efzofitimod clinical program. Efzofitimod previously received FDA orphan drug designation for systemic sclerosis (SSc). SAN DIEGO , Sept. 13, 2022 (GLOBE NEWSWIRE) -- aTyr Pharma, Inc. (Nasdaq: LIFE), a clinical stage biotherapeutics company engaged in the

SAN DIEGO – September 9, 2022 – aTyr Pharma, Inc. (Nasdaq: LIFE) (the “Company”), a biotherapeutics company engaged in the discovery and development of first-in-class medicines from its proprietary tRNA synthetase platform, today announced that Ashlee Dunston, Director of Investor Relations and

SAN DIEGO , Sept. 06, 2022 (GLOBE NEWSWIRE) -- aTyr Pharma, Inc. (Nasdaq: LIFE), a biotherapeutics company engaged in the discovery and development of first-in-class medicines from its proprietary tRNA synthetase platform, today announced that Sanjay S.